Induced proximity-based therapeutics for advanced prostate cancer
Open access0 citations
Abstract
Abstract Metastatic castration-resistant prostate cancers (mCRPC) remain dependent on androgen receptor (AR) signaling despite resistance to androgen-deprivation and AR-targeted therapies. Induced proximity-based therapeutics employ event-driven pharmacology to target AR, potentially overcoming resistance mechanisms. Herein, we highlight recent advances in induced proximity strategies targeting AR in mCRPC.
// Source
Authors: John Ching, Cindy H. Chau, William D. Figg
Institutions: National Cancer Institute, Office of the Director